Antidepressant drugs in the elderly

General Pharmacology

Volumn 30, Issue 4, 1998, Pages 465-475

  Gareri, Pietro ^a   Stilo, Giuseppe ^c   Bevacqua, Ida ^b   Mattace, Rosario ^b   Ferreri, Guido ^a   De Sarro, Giovambattista ^a  

^a Chair Pharmacol Chair Geriat F ^*  (Italy)

^b Fac Med   (Italy)

^c Via Barlaam Da Seminara 26 88100   (Italy)

Author keywords

Atypical antidepressants; Depression; Elderly; Lithium; MAO inhibitors; Pharmacodynamics; Pharmacokinetics; Tricyclics

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BUTRIPTYLINE; CLOMIPRAMINE; CORTICOSTEROID; DESIPRAMINE; DIGITALIS; DOSULEPIN; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM; MAPROTILINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; SEDATIVE AGENT; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

AGED; CARDIOTOXICITY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; HEART DISEASE; HUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SEDATION; SEIZURE; SUICIDAL BEHAVIOR;

AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSION; ELECTROCONVULSIVE THERAPY; HEART DISEASES; HUMANS; IMMUNITY, NATURAL; LITHIUM; MONOAMINE OXIDASE INHIBITORS;

EID: 0032053994     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(97)00070-0     Document Type: Review

References (96)

1. Abernethy D. R., Greenblatt D. J., Shader R. I. Imipramine and desipramine disposition in the elderly. J.Pharmac. Exp. Ther. 232:1985;183-188.
2. Abou-Saleh M. T., Coppen M. A. The prognosis of depression in old age. the case for lithium therapy Br. J. Psychiatry. 143:1983;527-528.
3. Alexanderson B., Price Evans D. A., Sjoqvist F. Steady state plasma levels of nortriptyline in twins. influence of genetic factors and drug therapy Br. Med. J. 2:1969;764-768.
4. Allen M. R. Sedativo-ipnotici ed ansiolitici anche nell'anziano. Geriatrics. 4:1987;51-58.
5. Amrein R., Allen S. R., Guentert T. W., Hartmann D., Lorscheid T., Schoerlin M. P., Yranesic D. The pharmacology of reversible monoamine oxidase inhibitors. Br. J. Psychiatry. 155:1989;66-71.
6. Auster R. Sertraline. a new antidepressant Am. Fam. Phys. 48:1993;311-314.
7. Beers M. H., Ouslander J. G. Risk factors in geriatric drug prescribing. Drugs. 37:1989;105-112.
8. Blazer D. Depression in the elderly. N. Engl. J. Med. 320:1989;164-166.
9. Bolden-Watson C., Richelson E. Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 52:1993;1023-1029.
10. Bressler R., Katz M. D. Drug therapy for geriatric depression. Drugs Aging. 3(3):1993;195-219.
11. Caird F. I., Andrews G. R., Kennedy R. D. Effect of posture on blood pressure in the elderly. Br. Heart J. 35:1973;527-530.
12. Casey D. A. Depression in the elderly. South. Med. J. 87:1994;559-563.
13. Cassano G. B., Musetti L., Soriani A., Savino M. The pharmacologic treatment of depression. drug selection criteria Pharmacopsychiatry. 26:1993;17-23.
14. Charatan F. B. The aged. Hankoff L. D. Suicide. Theory and Clinical Aspects:1979;253-262 PSG Publishing Co, Littleton, MA.
15. Clark D. W. J. Genetically determined variability in acetylation and oxidation. therapeutic implications Drugs. 29:1985;342-375.
16. Clerc G. E., Ruimy P. and Verdeau-Pailles J. on behalf of the Venlafaxine French Inpatient Study Group. (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Intern. Clin. Psychopharm. 9, 139-143.
17. Danion J. M. Anti-depressive agents and memory. Encephale. 19:1993;417-422.
18. Dawling S., Crome P., Braithwaite R. A. Pharmacokinetics of single oral doses of nortriptyline in depressed elderly hospital patients and young elderly volunteers. Clin. Pharmacokin. 5:1980;394-401.
19. DeAngelis L. Lithium treatment and the geriatric population. Int. J. Clin. Pharmac. Ther. and Toxic. 28:1990;394-398.
20. De Leo D. and Pavan L. (1993) Terapia farmacologic dei disturbi dell'umore. In Trattato di Gerontologia e Geriatria (Edited by Crepaldi G.), pp. 990-1008. UTET.
21. Demling J. Mianserin. pharmacology and clinical aspects of an effective antidepressive agent Fortschr. Med. 111:1993;497-500.
22. Ereshefsky L., Tran-Johnson T., Davis C. M., Leroy A. P. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect evaluation of doxepin and imipramine-new data and review. Clin. Chem. 34:1988;863-880.
23. Finlayson R. E., Martin L. M. Recognition and management of depression in the elderly. Mayo Clin. Proc. 57:1982;115-120.
24. Flint A. J., Rifat S. L. A prospective study of lithium augmentation in antidepressant-resistant geriatric depression. J. Clin. Psychopharmacol. 14:1994;353-356.
25. Freidlander A. H., Kawakami K. K., Ganzell S., Fitten L. J. Dental management of the geriatric patient with major depression. Spec. Care Dentist. 13:1993;249-253.
26. Friedman J. R., Norman D. C., Yoshikawa T. T. Correlation of estimated renal function parameters versus 24-hour creatinine clearance in ambulatory elderly. JAGS. 37:1989;145-149.
27. Furlanut M., Benetello P. The pharmacokinetics of tricyclic antidepressant drugs in the elderly. Pharmacol. Res. 22:1990;15-25.
28. Fyer A. J., Gorman J. M. Phenelzine in social phobia. J. Clin. Psychophar. 6:1986;93-98.
29. Gainsborough N., Nelson M. L., Maskrey V., Swift C. G., Jackson S. H. The pharmacokinetics and pharmacodynamics of medifoxamine after oral administration in healthy elderly volunteers. Eur. J. Clin. Pharmacol. 46:1994;163-166.
30. Galeotta G., Paoletti V., Mammarella A., Falaschi R. La terapia farmacologica nel paziente anziano. Clin. Ter. 135:1990;181-192.
31. Garattini S., Samanin R. Biochemical hypothesis on antidepressant drugs. a guide for clinicians or a toy for pharmacologists? Psychol. Med. 18:1988;287-304.
32. Geretsegger C., Bohmer F., Ludwig M. Paroxetine in the elderly depressed patients. randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects Int. Clin. Psychopharmacol. 9:1994;25-29.
33. Glassman A. H., Preud'homme X. A. Review of the cardiovascular effects of heterocyclic antidepressants. J. Clin. Psychiatry. 54:1993;16-22.
34. Glassman A. H., Roose S. P. Risks of antidepressants in the elderly. tricyclic antidepressants and arrhythmia-revising risks Gerontology. 40:1994;15-20.
35. Gonzalez F. J., Skoda R. C., Kinenza S. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. (Lond.) 331:1988;442-446.
36. Greenblatt D. J., Sellers E. M., Shader R. I. Drug disposition in old age. N. Engl. J. Med. 306:1982;1081-1088.
37. Guentert T. W., Tucker G., Korn A., Prefen J. P., Haefelfinger P., Schoerlin M. P. Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days. Acta Psychiatr. Scand. 82:1990;91-93.
38. Halaris A. Antidepressant drug therapy in the elderly. enchancing safety and compliance Int. J. Psychiatry Med. 16:1987;1-19.
39. Haria M., Fitton A., McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 4:1994;331-355.
40. Harris M. G., Benfield P. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in older patients with depressive illness. Drugs Aging. 6:1995;64-84.
41. Hauger R. L., Scheinin M., Siever L. J. Dissociation of norepinephrine turnover from α2 responses after clorgyline. Clin. Pharm. Ther. 43:1988;32-38.
42. Hewick D. S., Newbury P., Hopwood S., Naylor G., Moody J. Age as a factor affecting lithium therapy. Br. J. Clin. Pharmac. 4:1977;201-205.
43. Hiemke C. Paroxetine. pharmacokinetics and pharmacodynamics Fortschr. Neurol. Psychiatr. 62:1994;2-8.
44. Holliday S. M., Plosker G. L. Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy. Drugs Aging. 3:1993;278-299.
45. Jarvik L. F., Mitz J., Steuer J. Treating geriatric depression. JAGS. 30:1982;713-717.
46. Jefferson J. W. A review of the cardiovascular effects and toxicity of tricyclic antidepressants. Psychosom. Med. 37:1975;160-179.
47. Kan J. P., Strolin Benedetti M. Antagonism between long acting monoamineoxidase inhibitors (MAOI) and MD 780515, a new specific and reversible MAOI. Life Sci. 26:1980;2165-2171.
48. Katz I. R. Drug treatment of depression in the frail elderly. discussion of the NIH Consensus Development Conferenceon the Diagnosis and Treatment of Depression in Late Life Psychopharmacol. Bull. 29:1993;101-108.
49. Katz I. R., Streim J., Parmeles P. Prevention of depression, recurrence and complications in late life. Prev. Med. 23:1994;743-750.
50. Kelly C., Roche S., Naguib M., Webb S., Roberts M., Pitt B. A prospective evaluation of the hepatotoxicity of lofepramine in the elderly. Int. Clin. Psychopharmacol. 8:1993;83-86.
51. Koenig H. G. Treatment considerations for the depressed geriatric medical patient. Drugs Aging. 1:1991;266-278.
52. Korn A., Da Prada M., Raffesberg W., Allen S., Gasic S. Tyramine pressure effect in man. studies with moclobemide, a novel reversible monoamine oxidase inhibitor J. Neural. Transm. 26:1988;57-71.
53. Lamy P. P. Geriatric drug therapy. Am. Fam. Phys. 34:1986;118-124.
54. Leinonen E., Koponen H., Lepola U. Delirium during fluoxetine treatment. A case report. Ann. Clin. Psychiatry. 5:1993;255-257.
55. Leinonen E., Koponen H., Lepola U. Serum mianserin and ageing. Prog. Neuropsychopharmacol. Biol. Psychiatry. 18:1994;833-845.
56. Lim H. L. A practical approach to the management of depression. Singapore Med. J. 34:1993;449-451.
57. Luo H., Richardson J. S. A pharmacological comparison of citalopram, a bicyclic serotonin uptake inhibitor, with traditional tricyclic antidepressants. Int. Clin. Psychopharmacol. 8:1993;3-12.
58. Maguire K., Pereira A., Tiller J. Moclobemide pharmacokinetics in depressed patients. lack of age effect Hum. Psychopharmacol. 6:1991;249-252.
59. Markianos M., Alevizos V., Stafanis C. Plasma sex hormones and urinary biogenic amine metabolites during treatment of male depressed patients with the monoamine oxidase inhibitor moclobemide. Neuroendocrinol. Lett. 13:1991;49-55.
60. Martin A. J., Tebbs V. M., Ashford J. J. Affective disorders in general practice. Treatment of 6000 patients with fluvoxamine. Pharmatherapeutica. 5:1987;40-49.
61. Montamat S. C., Cusack B. J., Yestal R. E. Management of drug therapy in the elderly. N. Engl. J. Med. 321:1989;303-309.
62. Monti J. M., Alterwain P., Monti D. The effect of moclobemide on nocturnal sleep of depressed patients. J. Affect. Disord. 20:1990;201-208.
63. Murphy J. M., Olivier D. C., Monson R. R., Sobol A. M., Leighton A. Incidence of depression and anxiety. Am. J. Publ. Health. 78:1988;534-540.
64. Nair N. P. V., Ahmed S. K., Ng Ying Kin N. M. K., West T. E. G. Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients. Acta Psychiatr. Scand. 91:1995;28-35.
65. Nemeroff C. B. Paroxetine. an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression J. Clin. Psychopharmacol. 13:1993;10S-17S.
66. Nemeroff C. B. Evolutionary trends in the pharmacotherapeutic management of depression. J. Clin. Psychiatry. 55:1994;3-17.
67. Oxenkrug G. F., McCauley R., McIntyre I. M., Filipwicz C. Selective inhibition of MAO-A but not MAO-B activity increases rat pineal melatonin. J. Neural. Transm. 61:1985;265-270.
68. Potter W. Z., Calil H. M., Manian A. A., Zavadil A. P., Goodwin F. K. Hydroxylated metabolites of tricyclic antidepressants. Biol. Psych. 14:1979;601-613.
69. Potter W. Z., Rudorfer M. V., Manji H. The pharmacologic treatment of depression. N. Engl. J. Med. 325:1991;633-642.
70. Ramaekers J. G., Swijgman H. F., O'Hanlon J. F. The effect of moclobemide and mianserine on highway driving, psychometric performance and subjective parameters, relative to placebo. Psychopharmacology. 106:1992;562-567.
71. Rubin E. H., Biggs J. T., Preskorn S. H. Nortriptyline pharmacokinetics and plasma levels. implications for clinical practice J. Clin. Psyc. 46:1985;418-424.
72. Rudolph R., Entsuah R., Derivan A. Early clinical response in depression to venlafaxine hydrochloride. Biological Psychiatry. 29:1991;630S.
73. Safar M. Ageing and its effects on the cardiovascular system. Drugs. 39:1990;1-8.
74. Salzman C. A primer on geriatric psychopharmacology. Am. J. Psych. 139:1982;67-74.
75. Salzman C. Pharmacological treatment of depression in the elderly. J. Clin. Psychiatry. 54:1993;23-28.
76. Samuelian J. C., Tatossian A., Hackett D. A randomized, double-blind, parallel group comparison of venlafaxine and clomipramine in outpatients with major depression. Clin. Neuropharm. 15:1992;324B.
77. Scheinin M., Koulu M., Karhuvaara S., Zimmer R. H. Evidence that the reversible MAO-A inhibitor moclobemide increases prolactin secretion by a serotoninergic mechanism in healthy male volunteers. Life Sci. 47:1990;1491-1499.
78. Schweitzer E., Weisse C., Clary C., Fox I., Rickels K. Placebo-controlled trial of venlafaxine for the treatment of major depression. J. Clin. Psychopharmacol. 11:1991;233-236.
79. Schweitzer E., Feighner J., Mandos L. A., Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J. Clin. Psychiatry. 55:1994;104-108.
80. Shrivastava R. K., Cohn C., Crowder J., Davidson J., Dunner D., Feighner J., Kief A., Patrick R. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J. Clin. Psychopharmacol. 14:1994;322-329.
81. Small G. W. Recognition and treatment of depression in the elderly. J. Clin. Psych. 56:1991;11-22.
82. Stoeckel K., Pfefen J. P., Mayerson M., Schoerlin M. P., Andressen C., Ohnhaus E. E., Frey F., Guentert T. W. Absorption and disposition of moclobemide in patients with advanced age or reduced liver and kidney function. Acta Psychiatr. Scand. 82:1990;94-97.
83. Stollmaier W., Cimander K. F., Wagner W. Efficacy and tolerance of fluvoxamine in depressive syndromes in the practice. The results of a multicentered study on 2296 patients. Nervenheilkunde. 8:1989;247-252.
84. Sugrue M. F. Current concepts on the mechanism of action of antidepressant drugs. Pharm. Ther. 13:1981;219-224.
85. Ten-Holt W. L., Klaassen C. H., Schrijver G. Severe hyponatremia, possibly due to inappropriate antidiuretic hormone secretion, during use of the antidepressant fluoxetine. Ned. Tijdschr. Geneeskd. 138:1994;1181-1183.
86. Van Laar M. W., Van Willigenburg A. P., Volkerts E. R. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions and daytime sleepiness in healthy adult and elderly subjects. J. Clin. Psychopharmacol. 15(1):1995;30-40.
87. Veith R. C., Raskind M. A., Caldwell J. H. Cardiovascular effect of tricyclic antidepressants in depressed patients with chronic heart disease. N. Engl. J. Med. 306:1982;954-959.
88. Voltz H. P., Moller H. J. Antidepressant drug therapy in the elderly - A critical review of the controlled clinical trials conducted since 1980. Pharmacopsychiatry. 27(3):1994;93-100.
89. Von Moltke L. L., Greenblatt D. J., Shader R. I. Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications. Clin. Pharmacokinet. 24:1993;141-160.
90. Wallace S. M., Werbeeck R. K. Plasma protein binding of drugs in the elderly. Clin. Phamacokin. 12:1987;41-72.
91. Weissman M. M., Myers J. K. Affective disorders in a U.S. urban community. Arch. Gen. Psych. 35:1978;1304-1311.
92. Wesnes K. A., Simpson P. M., Christmas L., Anand R., McClelland G. R. The effects of moclobemide on cognition. J. Neural. Transm. 28:1989;91-102.
93. West E. D. and Dally P. (1959) Effect of iproniazid on depressive syndromes. Br. Med. J. 1491-1494.
94. Wilde M. I., Plosker G. L., Benfield P. Fluvoxamine. An updated review of its pharmacology and therapeutical use in depressive illness. Drugs. 46:1993;895-924.
95. Wilde M. I., Benfield P. Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs. 49:1995;411-439.
96. Zimmer R., Gieschke R., Firschbach R., Gasic S. Interaction studies with moclobemide. Acta Psychiatr. Scand. 82:1990;84-86.